Beta-Blocker Use in Hypertension and Heart Failure (A Secondary Analysis of the Systolic Blood Pressure Intervention Trial)

Given the concern that beta-blocker use may be associated with an increased risk for heart failure (HF) in populations with normal left ventricular systolic function, we evaluated the association between beta-blocker use and incident HF events, as well as loop diuretic initiation in the Systolic Blo...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The American journal of cardiology 2022-02, Vol.165, p.58-64
Hauptverfasser: Silverman, Daniel N., de Lavallaz, Jeanne du Fay, Plante, Timothy B., Infeld, Margaret M., Goyal, Parag, Juraschek, Stephen P., Dougherty, Geoff B., Callas, Peter W., Meyer, Markus
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 64
container_issue
container_start_page 58
container_title The American journal of cardiology
container_volume 165
creator Silverman, Daniel N.
de Lavallaz, Jeanne du Fay
Plante, Timothy B.
Infeld, Margaret M.
Goyal, Parag
Juraschek, Stephen P.
Dougherty, Geoff B.
Callas, Peter W.
Meyer, Markus
description Given the concern that beta-blocker use may be associated with an increased risk for heart failure (HF) in populations with normal left ventricular systolic function, we evaluated the association between beta-blocker use and incident HF events, as well as loop diuretic initiation in the Systolic Blood Pressure Intervention Trial (SPRINT). SPRINT demonstrated that a blood pressure target of
doi_str_mv 10.1016/j.amjcard.2021.10.049
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8766945</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0002914921011048</els_id><sourcerecordid>2619204087</sourcerecordid><originalsourceid>FETCH-LOGICAL-c495t-40371c44d35db23c11c9d42ae348c6c2a7e31f6dd0d2f1a6a08f7bb1647302393</originalsourceid><addsrcrecordid>eNqFkUFvEzEQhS0EoqHwE0CWuJTDBnvt9a4voLSipFIlkNqeLceepQ4bO7W9kSL-PF4SKuDCyfL4e88z8xB6TcmcEirer-d6szY62nlNalpqc8LlEzSjXSsrKil7imaEkLqSlMsT9CKldblS2ojn6IRxSQQTYoZ-nEPW1fkQzHeI-C4Bdh4v91uIGXxywWPtLV6CjhlfajeMEfDZAt-ACd7quMcLr4d9cgmHHud7wDf7lMPgDC6eweKvEVKaRFc-Q9yBz5PnbXR6ePcSPev1kODV8TxFd5efbi-W1fWXz1cXi-vKcNnkihPWUsO5ZY1d1cxQaqTltQbGOyNMrVtgtBfWElv3VAtNur5drajgLSM1k-wUfTj4bsfVBqwpTUQ9qG10mzKBCtqpv1-8u1ffwk51rRCSN8Xg7GgQw8MIKauNSwaGQXsIY1K1oIRT0jW8oG__QddhjGVHvyhZE066tlDNgTIxpBShf2yGEjXFq9bqGK-a4p3KJd6ie_PnJI-q33kW4OMBgLLPnYOoknHgDVgXwWRlg_vPFz8Bt8m5tA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2619204087</pqid></control><display><type>article</type><title>Beta-Blocker Use in Hypertension and Heart Failure (A Secondary Analysis of the Systolic Blood Pressure Intervention Trial)</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><source>ProQuest Central UK/Ireland</source><creator>Silverman, Daniel N. ; de Lavallaz, Jeanne du Fay ; Plante, Timothy B. ; Infeld, Margaret M. ; Goyal, Parag ; Juraschek, Stephen P. ; Dougherty, Geoff B. ; Callas, Peter W. ; Meyer, Markus</creator><creatorcontrib>Silverman, Daniel N. ; de Lavallaz, Jeanne du Fay ; Plante, Timothy B. ; Infeld, Margaret M. ; Goyal, Parag ; Juraschek, Stephen P. ; Dougherty, Geoff B. ; Callas, Peter W. ; Meyer, Markus</creatorcontrib><description>Given the concern that beta-blocker use may be associated with an increased risk for heart failure (HF) in populations with normal left ventricular systolic function, we evaluated the association between beta-blocker use and incident HF events, as well as loop diuretic initiation in the Systolic Blood Pressure Intervention Trial (SPRINT). SPRINT demonstrated that a blood pressure target of &lt;120 mm Hg reduced cardiovascular outcomes compared with &lt;140 mm Hg in adults with at least one cardiovascular risk factor and without HF. The lower rate of the composite primary outcome in the 120 mm Hg group was primarily driven by a reduction in HF events. Subjects on a beta blocker for the entire trial duration were compared with subjects who never received a beta blocker after 1:1 propensity score matching. A competing risk survival analysis by beta-blocker status was performed to estimate the effect of the drug on incident HF and was then repeated for a secondary end point of cardiovascular disease death. Among the 3,284 propensity score–matched subjects, beta-blocker exposure was associated with an increased HF risk (hazard ratio 5.86; 95% confidence interval 2.73 to 13.04; p &lt;0.001). A sensitivity analysis of propensity score–matched cohorts with a history of coronary artery disease or atrial fibrillation revealed the same association (hazard ratio 3.49; 95% confidence interval 1.15 to 10.06; p = 0.028). In conclusion, beta-blocker exposure in this secondary analysis was associated with increased incident HF in subjects with hypertension without HF at baseline.</description><identifier>ISSN: 0002-9149</identifier><identifier>EISSN: 1879-1913</identifier><identifier>DOI: 10.1016/j.amjcard.2021.10.049</identifier><identifier>PMID: 34906366</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Acute coronary syndromes ; Adrenergic beta-Antagonists - therapeutic use ; Aged ; Antihypertensive Agents - therapeutic use ; Antihypertensives ; Aortic aneurysms ; Atrial Fibrillation - epidemiology ; Beta blockers ; Blood Pressure ; Cardiovascular disease ; Cardiovascular diseases ; Confidence intervals ; Congestive heart failure ; Coronary artery ; Coronary artery disease ; Coronary Artery Disease - epidemiology ; Coronary vessels ; Diuretics ; Electrocardiography ; Enrollments ; Female ; Fibrillation ; Health hazards ; Health risks ; Heart failure ; Heart Failure - epidemiology ; Heart rate ; Humans ; Hypertension ; Hypertension - drug therapy ; Hypertension - epidemiology ; Incidence ; Male ; Middle Aged ; Morbidity ; Patient Care Planning ; Patients ; Propensity Score ; Proportional Hazards Models ; Risk analysis ; Risk Factors ; Secondary analysis ; Sensitivity analysis ; Sodium Potassium Chloride Symporter Inhibitors - therapeutic use ; Stroke ; Survival analysis ; Vein &amp; artery diseases ; Ventricle ; Vital signs</subject><ispartof>The American journal of cardiology, 2022-02, Vol.165, p.58-64</ispartof><rights>2021</rights><rights>Published by Elsevier Inc.</rights><rights>Copyright Elsevier Limited Feb 15, 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c495t-40371c44d35db23c11c9d42ae348c6c2a7e31f6dd0d2f1a6a08f7bb1647302393</citedby><cites>FETCH-LOGICAL-c495t-40371c44d35db23c11c9d42ae348c6c2a7e31f6dd0d2f1a6a08f7bb1647302393</cites><orcidid>0000-0001-7474-3737 ; 0000-0002-0806-1786 ; 0000-0002-3840-4081 ; 0000-0002-9000-0631 ; 0000-0001-9992-9597 ; 0000-0002-1923-6166</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/2619204087?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>230,314,780,784,885,3550,27924,27925,45995,64385,64387,64389,72469</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34906366$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Silverman, Daniel N.</creatorcontrib><creatorcontrib>de Lavallaz, Jeanne du Fay</creatorcontrib><creatorcontrib>Plante, Timothy B.</creatorcontrib><creatorcontrib>Infeld, Margaret M.</creatorcontrib><creatorcontrib>Goyal, Parag</creatorcontrib><creatorcontrib>Juraschek, Stephen P.</creatorcontrib><creatorcontrib>Dougherty, Geoff B.</creatorcontrib><creatorcontrib>Callas, Peter W.</creatorcontrib><creatorcontrib>Meyer, Markus</creatorcontrib><title>Beta-Blocker Use in Hypertension and Heart Failure (A Secondary Analysis of the Systolic Blood Pressure Intervention Trial)</title><title>The American journal of cardiology</title><addtitle>Am J Cardiol</addtitle><description>Given the concern that beta-blocker use may be associated with an increased risk for heart failure (HF) in populations with normal left ventricular systolic function, we evaluated the association between beta-blocker use and incident HF events, as well as loop diuretic initiation in the Systolic Blood Pressure Intervention Trial (SPRINT). SPRINT demonstrated that a blood pressure target of &lt;120 mm Hg reduced cardiovascular outcomes compared with &lt;140 mm Hg in adults with at least one cardiovascular risk factor and without HF. The lower rate of the composite primary outcome in the 120 mm Hg group was primarily driven by a reduction in HF events. Subjects on a beta blocker for the entire trial duration were compared with subjects who never received a beta blocker after 1:1 propensity score matching. A competing risk survival analysis by beta-blocker status was performed to estimate the effect of the drug on incident HF and was then repeated for a secondary end point of cardiovascular disease death. Among the 3,284 propensity score–matched subjects, beta-blocker exposure was associated with an increased HF risk (hazard ratio 5.86; 95% confidence interval 2.73 to 13.04; p &lt;0.001). A sensitivity analysis of propensity score–matched cohorts with a history of coronary artery disease or atrial fibrillation revealed the same association (hazard ratio 3.49; 95% confidence interval 1.15 to 10.06; p = 0.028). In conclusion, beta-blocker exposure in this secondary analysis was associated with increased incident HF in subjects with hypertension without HF at baseline.</description><subject>Acute coronary syndromes</subject><subject>Adrenergic beta-Antagonists - therapeutic use</subject><subject>Aged</subject><subject>Antihypertensive Agents - therapeutic use</subject><subject>Antihypertensives</subject><subject>Aortic aneurysms</subject><subject>Atrial Fibrillation - epidemiology</subject><subject>Beta blockers</subject><subject>Blood Pressure</subject><subject>Cardiovascular disease</subject><subject>Cardiovascular diseases</subject><subject>Confidence intervals</subject><subject>Congestive heart failure</subject><subject>Coronary artery</subject><subject>Coronary artery disease</subject><subject>Coronary Artery Disease - epidemiology</subject><subject>Coronary vessels</subject><subject>Diuretics</subject><subject>Electrocardiography</subject><subject>Enrollments</subject><subject>Female</subject><subject>Fibrillation</subject><subject>Health hazards</subject><subject>Health risks</subject><subject>Heart failure</subject><subject>Heart Failure - epidemiology</subject><subject>Heart rate</subject><subject>Humans</subject><subject>Hypertension</subject><subject>Hypertension - drug therapy</subject><subject>Hypertension - epidemiology</subject><subject>Incidence</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Morbidity</subject><subject>Patient Care Planning</subject><subject>Patients</subject><subject>Propensity Score</subject><subject>Proportional Hazards Models</subject><subject>Risk analysis</subject><subject>Risk Factors</subject><subject>Secondary analysis</subject><subject>Sensitivity analysis</subject><subject>Sodium Potassium Chloride Symporter Inhibitors - therapeutic use</subject><subject>Stroke</subject><subject>Survival analysis</subject><subject>Vein &amp; artery diseases</subject><subject>Ventricle</subject><subject>Vital signs</subject><issn>0002-9149</issn><issn>1879-1913</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkUFvEzEQhS0EoqHwE0CWuJTDBnvt9a4voLSipFIlkNqeLceepQ4bO7W9kSL-PF4SKuDCyfL4e88z8xB6TcmcEirer-d6szY62nlNalpqc8LlEzSjXSsrKil7imaEkLqSlMsT9CKldblS2ojn6IRxSQQTYoZ-nEPW1fkQzHeI-C4Bdh4v91uIGXxywWPtLV6CjhlfajeMEfDZAt-ACd7quMcLr4d9cgmHHud7wDf7lMPgDC6eweKvEVKaRFc-Q9yBz5PnbXR6ePcSPev1kODV8TxFd5efbi-W1fWXz1cXi-vKcNnkihPWUsO5ZY1d1cxQaqTltQbGOyNMrVtgtBfWElv3VAtNur5drajgLSM1k-wUfTj4bsfVBqwpTUQ9qG10mzKBCtqpv1-8u1ffwk51rRCSN8Xg7GgQw8MIKauNSwaGQXsIY1K1oIRT0jW8oG__QddhjGVHvyhZE066tlDNgTIxpBShf2yGEjXFq9bqGK-a4p3KJd6ie_PnJI-q33kW4OMBgLLPnYOoknHgDVgXwWRlg_vPFz8Bt8m5tA</recordid><startdate>20220215</startdate><enddate>20220215</enddate><creator>Silverman, Daniel N.</creator><creator>de Lavallaz, Jeanne du Fay</creator><creator>Plante, Timothy B.</creator><creator>Infeld, Margaret M.</creator><creator>Goyal, Parag</creator><creator>Juraschek, Stephen P.</creator><creator>Dougherty, Geoff B.</creator><creator>Callas, Peter W.</creator><creator>Meyer, Markus</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TS</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>M7Z</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-7474-3737</orcidid><orcidid>https://orcid.org/0000-0002-0806-1786</orcidid><orcidid>https://orcid.org/0000-0002-3840-4081</orcidid><orcidid>https://orcid.org/0000-0002-9000-0631</orcidid><orcidid>https://orcid.org/0000-0001-9992-9597</orcidid><orcidid>https://orcid.org/0000-0002-1923-6166</orcidid></search><sort><creationdate>20220215</creationdate><title>Beta-Blocker Use in Hypertension and Heart Failure (A Secondary Analysis of the Systolic Blood Pressure Intervention Trial)</title><author>Silverman, Daniel N. ; de Lavallaz, Jeanne du Fay ; Plante, Timothy B. ; Infeld, Margaret M. ; Goyal, Parag ; Juraschek, Stephen P. ; Dougherty, Geoff B. ; Callas, Peter W. ; Meyer, Markus</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c495t-40371c44d35db23c11c9d42ae348c6c2a7e31f6dd0d2f1a6a08f7bb1647302393</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Acute coronary syndromes</topic><topic>Adrenergic beta-Antagonists - therapeutic use</topic><topic>Aged</topic><topic>Antihypertensive Agents - therapeutic use</topic><topic>Antihypertensives</topic><topic>Aortic aneurysms</topic><topic>Atrial Fibrillation - epidemiology</topic><topic>Beta blockers</topic><topic>Blood Pressure</topic><topic>Cardiovascular disease</topic><topic>Cardiovascular diseases</topic><topic>Confidence intervals</topic><topic>Congestive heart failure</topic><topic>Coronary artery</topic><topic>Coronary artery disease</topic><topic>Coronary Artery Disease - epidemiology</topic><topic>Coronary vessels</topic><topic>Diuretics</topic><topic>Electrocardiography</topic><topic>Enrollments</topic><topic>Female</topic><topic>Fibrillation</topic><topic>Health hazards</topic><topic>Health risks</topic><topic>Heart failure</topic><topic>Heart Failure - epidemiology</topic><topic>Heart rate</topic><topic>Humans</topic><topic>Hypertension</topic><topic>Hypertension - drug therapy</topic><topic>Hypertension - epidemiology</topic><topic>Incidence</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Morbidity</topic><topic>Patient Care Planning</topic><topic>Patients</topic><topic>Propensity Score</topic><topic>Proportional Hazards Models</topic><topic>Risk analysis</topic><topic>Risk Factors</topic><topic>Secondary analysis</topic><topic>Sensitivity analysis</topic><topic>Sodium Potassium Chloride Symporter Inhibitors - therapeutic use</topic><topic>Stroke</topic><topic>Survival analysis</topic><topic>Vein &amp; artery diseases</topic><topic>Ventricle</topic><topic>Vital signs</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Silverman, Daniel N.</creatorcontrib><creatorcontrib>de Lavallaz, Jeanne du Fay</creatorcontrib><creatorcontrib>Plante, Timothy B.</creatorcontrib><creatorcontrib>Infeld, Margaret M.</creatorcontrib><creatorcontrib>Goyal, Parag</creatorcontrib><creatorcontrib>Juraschek, Stephen P.</creatorcontrib><creatorcontrib>Dougherty, Geoff B.</creatorcontrib><creatorcontrib>Callas, Peter W.</creatorcontrib><creatorcontrib>Meyer, Markus</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Physical Education Index</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Biochemistry Abstracts 1</collection><collection>Research Library (Corporate)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The American journal of cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Silverman, Daniel N.</au><au>de Lavallaz, Jeanne du Fay</au><au>Plante, Timothy B.</au><au>Infeld, Margaret M.</au><au>Goyal, Parag</au><au>Juraschek, Stephen P.</au><au>Dougherty, Geoff B.</au><au>Callas, Peter W.</au><au>Meyer, Markus</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Beta-Blocker Use in Hypertension and Heart Failure (A Secondary Analysis of the Systolic Blood Pressure Intervention Trial)</atitle><jtitle>The American journal of cardiology</jtitle><addtitle>Am J Cardiol</addtitle><date>2022-02-15</date><risdate>2022</risdate><volume>165</volume><spage>58</spage><epage>64</epage><pages>58-64</pages><issn>0002-9149</issn><eissn>1879-1913</eissn><abstract>Given the concern that beta-blocker use may be associated with an increased risk for heart failure (HF) in populations with normal left ventricular systolic function, we evaluated the association between beta-blocker use and incident HF events, as well as loop diuretic initiation in the Systolic Blood Pressure Intervention Trial (SPRINT). SPRINT demonstrated that a blood pressure target of &lt;120 mm Hg reduced cardiovascular outcomes compared with &lt;140 mm Hg in adults with at least one cardiovascular risk factor and without HF. The lower rate of the composite primary outcome in the 120 mm Hg group was primarily driven by a reduction in HF events. Subjects on a beta blocker for the entire trial duration were compared with subjects who never received a beta blocker after 1:1 propensity score matching. A competing risk survival analysis by beta-blocker status was performed to estimate the effect of the drug on incident HF and was then repeated for a secondary end point of cardiovascular disease death. Among the 3,284 propensity score–matched subjects, beta-blocker exposure was associated with an increased HF risk (hazard ratio 5.86; 95% confidence interval 2.73 to 13.04; p &lt;0.001). A sensitivity analysis of propensity score–matched cohorts with a history of coronary artery disease or atrial fibrillation revealed the same association (hazard ratio 3.49; 95% confidence interval 1.15 to 10.06; p = 0.028). In conclusion, beta-blocker exposure in this secondary analysis was associated with increased incident HF in subjects with hypertension without HF at baseline.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>34906366</pmid><doi>10.1016/j.amjcard.2021.10.049</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0001-7474-3737</orcidid><orcidid>https://orcid.org/0000-0002-0806-1786</orcidid><orcidid>https://orcid.org/0000-0002-3840-4081</orcidid><orcidid>https://orcid.org/0000-0002-9000-0631</orcidid><orcidid>https://orcid.org/0000-0001-9992-9597</orcidid><orcidid>https://orcid.org/0000-0002-1923-6166</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0002-9149
ispartof The American journal of cardiology, 2022-02, Vol.165, p.58-64
issn 0002-9149
1879-1913
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8766945
source MEDLINE; Access via ScienceDirect (Elsevier); ProQuest Central UK/Ireland
subjects Acute coronary syndromes
Adrenergic beta-Antagonists - therapeutic use
Aged
Antihypertensive Agents - therapeutic use
Antihypertensives
Aortic aneurysms
Atrial Fibrillation - epidemiology
Beta blockers
Blood Pressure
Cardiovascular disease
Cardiovascular diseases
Confidence intervals
Congestive heart failure
Coronary artery
Coronary artery disease
Coronary Artery Disease - epidemiology
Coronary vessels
Diuretics
Electrocardiography
Enrollments
Female
Fibrillation
Health hazards
Health risks
Heart failure
Heart Failure - epidemiology
Heart rate
Humans
Hypertension
Hypertension - drug therapy
Hypertension - epidemiology
Incidence
Male
Middle Aged
Morbidity
Patient Care Planning
Patients
Propensity Score
Proportional Hazards Models
Risk analysis
Risk Factors
Secondary analysis
Sensitivity analysis
Sodium Potassium Chloride Symporter Inhibitors - therapeutic use
Stroke
Survival analysis
Vein & artery diseases
Ventricle
Vital signs
title Beta-Blocker Use in Hypertension and Heart Failure (A Secondary Analysis of the Systolic Blood Pressure Intervention Trial)
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-19T13%3A26%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Beta-Blocker%20Use%20in%20Hypertension%20and%20Heart%20Failure%20(A%20Secondary%20Analysis%20of%20the%20Systolic%20Blood%20Pressure%20Intervention%20Trial)&rft.jtitle=The%20American%20journal%20of%20cardiology&rft.au=Silverman,%20Daniel%20N.&rft.date=2022-02-15&rft.volume=165&rft.spage=58&rft.epage=64&rft.pages=58-64&rft.issn=0002-9149&rft.eissn=1879-1913&rft_id=info:doi/10.1016/j.amjcard.2021.10.049&rft_dat=%3Cproquest_pubme%3E2619204087%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2619204087&rft_id=info:pmid/34906366&rft_els_id=S0002914921011048&rfr_iscdi=true